BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  Schwarz  Pharma  AG  submitted  on  15  September  1999  an  application  for  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
NutropinAq,  in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the 
Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. M A Ainsworth 
Co-Rapporteur: 
Prof. Rolf Bass 
Licensing status: 
Nutropinaq  has  been  given  Marketing  Authorisations  in  USA  in  December  1996  for  the  indications 
GHD and CRI, and in March 1997 for the indication for Turner syndrome patients and in December 
1997 for GHD in adults.  
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 22 October 1999. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  
3  January 2000.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP 
members on 7 January 2000. 
During the meeting in February 2000 the CPMP agreed on the consolidated List of Questions to 
be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 18 
February 2000. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  
16 August 2000. 
A report of the inspection carried out at the manufacturing site Genentech Inc., San Francisco, 
CA, USA between 7-9 March 2000 was issued on 26 April 2000. 
The Rapporteur circulated the joint response Assessment Report on the company’s responses to 
the List of Questions to all CPMP members on 15 September 2000.  
The Rapporteur circulated the joint response Assessment Report on the company’s responses to 
the remaining pharmaceutical clarifications, to all CPMP members on 13 October 2000. 
The  company, Schwarz Pharma AG, provided on 13 October 2000, a letter of  undertaking on 
the follow-up measures (pharmaceutical issues), to be fulfilled as requested by the CPMP. 
During the meeting on 17-19 October 2000 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to NutropinAq on 19 October 2000. 
1/1 
EMEA 2004 
 
  
